BETHESDA, Md., Sept. 2 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) ("Micromet" or the "Company"), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the appointment of Barclay A. Phillips as Senior Vice President and Chief Financial Officer. Mr. Phillips has served as a member of the Company's board of directors since 2000, and was the chair of the nominating & corporate governance committee and a member of the audit committee. In connection with his joining the executive management team of Micromet, Mr. Phillips has resigned from the board and the committees he served on.
"We are very excited to have Buck Phillips become a member of our executive management team," commented Christian Itin, President and Chief Executive Officer, and a member of Micromet's Board. "While he served on the board of directors, Buck has gained intimate knowledge of our business, the development programs and the management team he is now joining. His financial and industry experience will be invaluable in continuing the high standard for the management of the financial affairs of Micromet that he has helped set as a member of our audit committee. We thank Buck for his service on the board, and look forward to his leadership and contributions in the development and implementation of our financing and business strategies."
"I have had the opportunity to work with and invest in many
biotechnology companies. I believe Micromet is unique in terms of the
breadth of its proprietary technology, its clinical validation as evidenced
by the recent article in Science magazine, and its strong management team,"
stated Mr. Phillips. "I look forward to
|SOURCE Micromet, Inc.|
Copyright©2008 PR Newswire.
All rights reserved